News | July 06, 2024
Dabur India updates on Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Dr. Sanjay Behari, Director of Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, as the President of the Medical Assessment and Rating Board
Yann d’Hervé takes over responsibility for the Health Care business at Evonik, effective July 1
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
The initiative aims to empower individuals to take proactive steps towards monitoring their health
Ibara will drive AI-powered clinical research innovation
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Subscribe To Our Newsletter & Stay Updated
